Articles

A study explores how supply and demand impact the value of medication.

How Drug Shortages Affect Drug Pricing in China

Novartis anticipates Fabhalta to be available in the United States in December for the treatment of paroxysmal nocturnal hemoglobinuria. 

Fabhalta Gains FDA Approval for Treatment of Paroxysmal Nocturnal Hemoglobinuria 

Eli Lilly and Company's obesity drug Zepbound (tirzepatide) has a list price of $1,059.87, which is approximately 20% less than the 2.4 mg semaglutide injection indicated for weight loss.

Obesity Treatment Zepbound Now Available in United States

Johnson & Johnson’s TAR-200 has a novel targeted releasing system that allows for a controlled release of gemcitabine in patients with Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer.

Investigational Treatment for High-Risk Bladder Cancer Awarded FDA Breakthrough Designation

Opdivo (nivolumab) plus cisplatin-based chemotherapy shows improved survival benefits in the first-line treatment of adults with unresectable or metastatic urothelial carcinoma.

Opdivo Combination Granted FDA Priority Review for Unresectable, Metastatic Urothelial Carcinoma

Critical factors need to be addressed for pharma stakeholders to realize the full potential of generative artificial intelligence.

Generative Artificial Intelligence Could Transform Healthcare if Challenges Are Addressed

Jaypirca (pirtobrutinib) is indicated for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who received at least two prior lines of treatment with a Bruton tyrosine kinase inhibitor and a BCL2 inhibitor.

FDA Grants Pirtobrutinib Accelerated Approval for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 

Ongoing clinical trials are evaluating zotatifin (eFT226) plus Faslodex (fulvestrant) and Verzenio (abemaciclib) for the treatment of ER–positive, HER2-negative advanced or metastatic breast cancer. 

Triplet Combination for Breast Cancer Gets FDA Fast Track Designation

In clinical trials, Keytruda plus Padcev lowered the risk of disease progression or death by 55% compared with chemotherapy in adult patients with locally advanced or metastatic urothelial carcinoma.

FDA Priority Review Granted to Keytruda/Padcev Combo for Locally Advanced, Metastatic Urothelial Carcinoma

Sphingosine-1-phosphate receptor modulator is designed to improve leukemia-free survival by increasing graft-versus-leukemia response.

News